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Intracellular targets of cyclin-dependent kinase inhibitors:
identification by affinity chromatography using immobilised
inhibitors
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Background: Chemical inhibitors of cyclin-dependent kinases (CDKs) have
great therapeutic potential against various proliferative and neurodegenerative
disorders. Olomoucine, a 2,6,9-trisubstituted purine, has been optimized for
activity against CDK1/cyclin B by combinatorial and medicinal chemistry efforts
to yield the purvalanol inhibitors. Although many studies support the action of
purvalanols against CDKs, the actual intracellular targets of 2,6,9-trisubstituted
purines remain unverified.
Results: To address this issue, purvalanol B (95) and an N6-methylated,
CDK-inactive derivative (95M) were immobilized on an agarose matrix. Extracts
from a diverse collection of cell types and organisms were screened for
proteins binding purvalanol B. In addition to validating CDKs as intracellular
targets, a variety of unexpected protein kinases were recovered from the 95
matrix. Casein kinase 1 (CK1) was identified as a principal 95 matrix binding
protein in Plasmodium falciparum, Leishmania mexicana, Toxoplasma gondii
and Trypanosoma cruzi. Purvalanol compounds also inhibit the proliferation of
these parasites, suggesting that CK1 is a valuable target for further screening
with 2,6,9-trisubstituted purine libraries.
Conclusions: That a simple batchwise affinity chromatography approach using
two purine derivatives facilitated isolation of a small set of highly purified
kinases suggests that this could be a general method for identifying
intracellular targets relevant to a particular class of ligands. This method allows
a close correlation to be established between the pattern of proteins bound to
a small family of related compounds and the pattern of cellular responses to
these compounds. 
Introduction
Cyclin-dependent kinases (CDKs) are active as complexes
comprising a catalytic subunit and a regulatory subunit
(cyclin). Nine CDK proteins and eleven cyclins have been
identified in man at present: CDK1 (associated with cyclin
B), CDK2 (cyclin A, cyclin E), CDK3 (no associated cyclin
identified as yet), CDK4 (cyclin D1–D3), CDK5 (associ-
ated with noncyclin proteins, p35nck5a or p39), CDK6
(cyclin D1–D3), CDK7 (cyclin H), CDK8 (cyclin C) and
CDK9 (cyclin K, cyclin T). The CDKs associated with
cyclins F, G and I have not been identified as yet. CDKs
play a key role in cell-cycle control (CDKs 1–4, 6, 7), in thy-
mocyte apoptosis (CDK2), in neuronal functions (CDK5)
and in transcription (CDKs 7–9); for reviews see [1–4]. 
CDKs and their regulators are very frequently deregulated
in human tumours. CDK5 is also clearly important in neu-
rodegenerative disorders such as Alzheimer’s disease and
Parkinson’s disease. Stimulated by these observations and
by the first encouraging preclinical and clinical results
obtained with CDK inhibitors [5,6], the search for chemical
inhibitors of CDKs has intensified over the past few years
(for reviews see [7–10]). Several potent inhibitors have been
described: isopentenyladenine [11], staurosporine [11],
butyrolactone I [12], olomoucine [13], flavopiridol [14],
roscovitine [15,16], purvalanol [17], indirubins [18],
paullones [19,20] and hymenialdisine [21]. All CDK
inhibitors identified so far function by competing with ATP
for binding to the catalytic site. Many of these inhibitors
have been co-crystallised with CDK2 (for  a review see
[10]). Chemical inhibitors of CDKs may have therapeutic
applications in various human diseases such as tumoral pro-
liferation (200 types of cancers), nontumoral proliferation
(psoriasis, angiogenesis), cardiovascular diseases (undesired
vascular proliferation following angioplasty [restenosis] [22],
in arteriosclerosis [23] or atherosclerosis), renal diseases
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(glomerulonephritis) [24,25], parasitosis (e.g. proliferation of
protozoan organisms [e.g. Plasmodium, Toxoplasma, Try-
panosoma] [10], fungi, helminths), viral infections
(cytomegalovirus [26], HIV [27], Herpes simplex virus [28],
varicella-zoster virus [29]), and neurodegenerative disorders
(Alzheimer’s disease [21,30,31]). 
Since the discovery of 6-dimethylaminopurine [32,33] and
isopentenyladenine [11] as inhibitors of CDK1/cyclin B,
2,6,9-trisubstituted purines have been extensively investi-
gated as CDK inhibitors. Following on from classical
[13,15,34] or combinatorial chemistry synthesis [35–38],
thorough structure–activity relationship studies have been
performed, leading to increasingly active purines (for
review see [10]): 6-dimethylaminopurine (IC50 = 120 µM)
[32,33], isopentenyladenine (IC50 = 55 µM) [11], olo-
moucine (IC50 = 7 µM) [13], roscovitine (IC50 = 0.45 µM)
[16], amino-purvalanol (IC50 = 0.033 µM; 97) [39], pur-
valanol A and B (60 and 95; IC50 = 0.004–0.006 µM) [17].
As efficiency improved, we noticed a clear increase in
kinase selectivity, at least as could be judged from studies
performed on a panel of 25–30 kinases. Given the large
number of ATP-binding proteins present in cells, the
in vivo selectivity of CDK inhibitors remains open,
thereby limiting interpretations of the cellular effects of
CDK inhibitors. Several arguments support the idea that
CDK inhibitors act intracellularly by inhibiting CDKs.
First, the reported cell-cycle effects are compatible with
CDK inhibition (G1 arrest: inhibition of CDK2; G2/M
arrest: inhibition of CDK1) (for review see [8]). Second,
similar effects are obtained with structurally different
inhibitors. Last, a generally good correlation is observed
between the in vitro efficiency of inhibitors on CDKs, and
their in vivo efficacy on cells. These arguments are all
indirect, however, and the real spectrum of intracellular
targets of CDK inhibitors remains unknown. 
We therefore designed an affinity-chromatography
method to investigate the spectrum of intracellular targets
of purine CDK inhibitors. The CDK2–purvalanol crystal
structure [10,38] suggested that a linker could be attached
to the carboxylic acid of the 6-anilino substituent of the
inhibitor without interfering with its interaction with the
kinase. This sidechain was used to couple the compound
to an agarose matrix. As a control, an inactive N6-methy-
lated purvalanol was also immobilised on agarose. The
immobilised purvalanol beads (95 matrix) were used to
affinity purify interacting proteins from various cell types
and tissues. A series of very diverse examples demon-
strates that purvalanols interact intracellularly with CDKs
but also with several other kinases. 
Results
Structure and use of affinity chromatography media
An extensive structure–activity relationship study of
2,6,9-trisubstitued purines has led to the discovery of the
purvalanols (95, 97; Figure 1), a group of potent and selec-
tive CDK inhibitors [17,38]. The crystal structure of pur-
valanol B (95) in the active site of CDK2 shows that the
inhibitor nitrogen N6 donates a hydrogen bond to the
backbone of Leu83 [17]. Consequently, the addition of a
methyl group to N6 (95M; 97M) greatly reduces the CDK
inhibitory activity of the compounds [38]. The crystal
structure also shows that the 4-carboxyanilino substituent
faces the exterior of the kinase, making it ideally suited
for modification with a polyethylene glycol linker for cou-
pling to an agarose matrix (Figure 1). The crystal structure
also shows that N9 faces the inside of the ATP-binding
pocket and is therefore inaccessible to solvent. As another
control matrix, 95 was also linked to agarose beads through
the N9 position (Figure 1). The 95, 95M and 95 N9-linked
beads were stored as 33% slurries in bead buffer at 4°C
until use. Extracts from various biological models (oocytes,
mammalian tissues, protozoan parasites) were loaded on
the beads in batch for 30 min, under constant rotation, at
4°C. After extensive washing of the beads, the bound pro-
teins were resolved by 10% sodium dodecyl sulfate–poly-
acrylamide gel electrophoresis (SDS–PAGE) and analysed
either by western blotting, or by silver or Coomassie blue
staining. Some protein bands were excised from the gels,
digested with endolysine C, and the peptides separated by
HPLC and microsequenced. The peptide sequences and
identified proteins are shown in Figure 2. 
Oocytes and eggs
Starfish oocytes
We first started with one of our favourite cell-cycle
models, the starfish oocytes. These cells are naturally
arrested in prophase (P) and enter very synchronously into
metaphase (M) 20 min after stimulation by the hormone
1-methyladenine [39]. Aminopurvalanol (97), but not its
methylated derivative (97M) (Figure 1), inhibits this
prophase/metaphase transition (IC50 = 1.8 µM; data not
shown). Extracts were prepared from oocytes in prophase
or metaphase and loaded on 95, 95M and p9CKShs1 (a selec-
tive CDK1/2-binding protein) beads, and the bound pro-
teins were resolved by electrophoresis and detected by
silver staining or western blotting (Figure 3). Besides a
major 32 kDa protein that nonspecifically binds to all of
the resins, very few proteins interacted with the 95M
matrix. In contrast, several bands bound specifically to the
95 matrix (Figure 3). CDK1 and cyclin B were identified
by western blotting (Figure 3b,c). Interestingly, only
CDK1/cyclin B from metaphase oocytes bound to the
beads, whereas the signal was much reduced on beads
loaded with prophase oocytes (compare with the p9CKShs1
beads which retain both prophase and metaphase CDK1/
cyclin B). This reduced signal probably originates from
the small fraction of oocytes that spontaneously mature in
the prophase-arrested oocyte population. The lack of
binding of prophase CDK1/cyclin B to 95 matrix is proba-
bly the consequence of steric hindrance: prophase CDK1
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is phosphorylated on Thr14 and Tyr15, two sites located
at the ATP-binding site, whereas metaphase CDK1 is
dephosphorylated at both sites [40]. It has been reported
that ATP binds to the doubly phosphorylated CDK1; it is
therefore possible that the 95 matrix does not bind the
prophase form of CDK1 because the linker cannot be
accommodated owing to the presence of the two phospho-
rylated amino acids that are located just at the border of
the ATP-binding site. In addition, we identified two other
95-binding proteins (Figures 2 and 3a). An 80 kDa protein
(1), mostly detectable in prophase oocytes, yielded a
peptide fragment that displayed homology to a sequence
present in ribosomal S6 kinase II. Two peptides resulting
from a 53 kDa protein (2) shared great homology with
calmodulin-dependent kinase II (CaMKII). The presence
of both 80 and 53 kDa proteins on the 95 matrix loaded
with prophase oocyte extracts, despite the reduced level
of CDK1/cyclin B, suggests that these proteins bind
directly to the matrix rather than through CDK1/cyclin B.
In addition, both proteins did not bind to the p9CKShs1
matrix, which strongly binds CDK1. To further confirm
this, extracts were depleted of their CDK1/cyclin B on
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Figure 1
Chemical structures of the purvalanols
(95, 95M, 97, 97M) and synthetic schemes for
the 95-, 95M- and 95-N9 matrices.
(a) Chemical structures of 95, 95M, 97 and
97M. (b) Synthesis of the 95 and 95M
matrices. Conditions: (i) 7.0 equiv. of NaH,
14.0 equiv. of methyliodide, DMF, 12 h; (ii)
1.5 equiv. of NaOH, H2O/1,4-dioxane (1/1,
v/v), 12 h; (iii) 5.0 equiv. of R(—)2-amino-
3-methyl-1-butanol, 5.0 equiv. of
diisopropylethylamine (DIEA), n-butanol,
110°C, 18 h; (iv) 1.05 equiv. of
1,3-diisopropylcarbodiimide (DIC), 1.05 equiv.
of hydroxybenzotriazole, 2.0 equiv. of DIEA,
2.0 equiv. of 1-tertbutyloxycarbonyl-1,13-
diamino-4,7,10-trioxatridecane, 0.05 equiv. of
4-dimethylaminopyridine, DMF/CH2Cl2/
1,4-dioxane (1/1/1, v/v/v), 12 h;
(v) trifluoroacetic acid/CH2Cl2/H2O/(CH3)2S
(45/45/1/1, v/v/v/v), 12 h; (vi) 45.0 mM of
amine-bearing purine, 1.5 ml of ReactiGel®6×
(Pierce, No. 20259), 0.1 M aqueous K2CO3,
12 h. (c) Synthesis of the 95-N9 matrix.
Conditions: (i) 1.1 equiv. of 13-
tertbutoxycarbonylamino-3,6,9-trioxaundecan-
1-ol, 2.0 equiv diethylazodicarboxylate, 2.0
equiv. triphenylphosphine, 0°C to RT, 12 h;
(ii) 3.0 equiv. of 4-carboxy-3-chloroaniline,
3.0 equiv. of DIEA, n-butanol, 110°C, 12 h;
(iii) as (iii) above; (iv) see (v) above; (v) as
(vi) above.
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p9CKShs1 beads, before loading on 95 matrix (Figure 4).
This depletion did not decrease the levels of proteins 1
and 2, suggesting that their interactions with 95 matrix is
independent of CDK1/cyclin B. 
Lugworm oocytes
We then used another marine invertebrate model, the
lugworm Arenicola defodiens. Its oocytes are also naturally
arrested in prophase until stimulated by a brain hormone.
After stimulation, they progress into metaphase within
30 min where they remain arrested until fertilisation [41].
We loaded oocyte extracts on 95 and 95M matrices.
Three principal proteins (78, 56, 47 kDa) were found to
bind specifically to 95 matrix (Figure 5a). Consistent
with the results obtained from the starfish experiments,
proteins 1 and 3 were identified as ribosomal S6 kinase
II and Erk1, respectively (Figure 2). Peptides derived
from protein 2 could not be matched to any known
protein sequence, which suggests that this protein might
be a novel purine target. In addition, both CDK1 and
cyclin B were detected on 95 matrix by western blotting
(data not shown).
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Figure 2
95- and 95M-binding proteins identified by
microsequencing of internal peptides.
Proteins were purified from various cell and
tissue types by affinity chromatography on 95
and 95M matrices. Following resolution by
SDS–PAGE, individual proteins (numbered
for each species as shown in Figures 3–10)
were excised from the gel and digested by an
endopeptidase. The generated peptides were
separated using high performance liquid
chromatography (HPLC), and some were
microsequenced. Sequences were compared
with those present in protein databases.
Peptide sequences are presented under a
segment of the closest available protein
sequence: (a) mouse CDK5 (P49615),
(b) human Erk1 (P27361), (c) human Erk2
(Z11694) (porcine brain peptide, MCF-7
peptide), Xenopus Erk2 (P26696) (Xenopus
oocyte peptide), (d) Plasmodium PfCK1
(AF017139) [44], T. cruzi CK1 (AAF-00025)
(Trypanosoma peptides; Leishmania peptide),
Arabidopsis thaliana CK1 (CAA55397)
(Toxoplasma peptide), (e) rat Ca/calmodulin-
dependent kinase II (AAC14706) (first starfish
oocyte peptide), Xenopus Ca/calmodulin-
dependent kinase II (AAA57338) (Xenopus
oocyte peptide), Caenorhabditis elegans
Ca/calmodulin-dependent kinase
(CAA94244), (f) rat S6 kinase II (A53300),
(g) human biliverdin reductase (NP-000704),
(h) rat alcohol dehydrogenase (A26468),
(i) common brush-tailed possum inhibin
α subunit (AAC63945), hypohetical
Arabidopsis thaliana protein (AAD14450).
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Sea urchin eggs 
We then analysed sea urchin eggs, which have been fre-
quently used in cell-cycle studies. These cells are natu-
rally arrested in G1 until fertilisation triggers a series of
highly synchronous cell cycles [42]. Extracts were pre-
pared from unfertilised or metaphase eggs and incubated
with 95 and 95M matrices. Two major proteins (32 and
33 kDa) bound specifically to 95 matrix (Figure 5b). The
upper band cross-reacts strongly with anti-PSTAIRE anti-
bodies (Figure 5b) and might be either CDK1 or CDK2.
The nature of the lower band remains to be determined.
Xenopus oocytes
Xenopus laevis oocytes undergo maturation when stimu-
lated by progesterone. Some aspects of this transition
can be reproduced in cell-free extracts and they are
inhibited by 95 and 97 [43]. We prepared extracts from
prophase-arrested oocytes and from oocytes at the time
of nuclear-envelope breakdown (GVBD, germinal vesicle
breakdown), and loaded them on both matrices. Very few
proteins were detected on 95M (Figure 6a). A few pro-
teins specifically bound to 95 (84, 74, 62, 52, 45 and
33 kDa). Protein 5 was identified as X. laevis Erk2, protein
4 as CaMKII, and protein 6 remained an unresolvable
mixture (Figure 2). Western blotting allowed the detec-
tion of CDK1/CDK2 (anti-PSTAIRE antibodies) and of
Erk2 on 95 matrix, but not on 95M matrix (Figure 6b). As
in the starfish oocytes, CDK was only found in matured
oocytes, presumably because of the Thr14, Tyr15 phos-
phorylation of CDKs in prophase oocytes, which is likely
to hinder interaction with 95 matrix. Erk2 is inactive in
prophase-arrested oocytes and becomes activated during
progesterone-induced maturation. This activation by dual
phosphorylation of the TEY amino-acid motif is accompa-
nied by a shift in electrophoretic mobility of the kinase.
Erk2 was detected in both prophase and matured oocytes
(Figure 6b). Using slightly modified electrophoresis con-
ditions, we showed that the 95 matrix binds both the inac-
tive and active forms of Erk2 (Figure 6c).
Mammalian tissues and cells 
Rat tissues
Extracts were prepared from various tissues of a male rat
and loaded on 95 and 95M derivatized agarose. No bound
proteins were detected on 95M matrix by silver staining
(data not shown), except when loaded with a liver extract
which provided an abundant protein (Figure 7, first lane).
This 47 kDa protein (1) was identified as alcohol dehydro-
genase (Figure 2). It was essentially absent on 95 matrix
loaded with liver extracts, demonstrating the impressive
degree of selectivity achievable by this method. All tissues
contained 95-binding proteins, some of which seemed to
be shared by most tissues (such as a 42 kDa protein),
others appearing to be tissue-specific (Figure 7). The liver
contained a major 26 kDa 95-interacting protein, which
was identified as biliverdin reductase by microsequencing
(Figure 2). We are currently investigating the identity of
the 95 matrix binding proteins of some of these tissues.
Porcine brain
We then prepared an extract of porcine brain and loaded
it on 95 and 95M matrices. Although essentially no
protein was detected on 95M matrix, three conspicuous
proteins (1, 2, 3) bound specifically to 95 (46, 42, 35 kDa;
Figure 8a). They were identified as Erk1, Erk2 and
CDK5, respectively (Figure 2). Western blotting showed
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Figure 3
CDK1/cyclin B and two other proteins from
starfish oocytes bind to 95 matrix. Extracts
from starfish prophase (P) and metaphase (M)
oocytes were loaded on 95M or 95 matrix, or
p9CKShs1-sepharose. Bound proteins were
resolved by SDS–PAGE and revealed by
(a) silver staining and by western blotting with
(b) anti-cyclin B and (c) anti-PSTAIRE
antibodies. Proteins 1 and 2 were further
processed for microsequencing and identified
as S6 kinase II and calmodulin-dependent
kinase II, respectively (Figure 2). 
Starfish oocytes(a)
(b)
(c)
Cyclin B
CDK1
Extract   P   M    P    M     P
Extract     P   M   P   M   P   M
Beads      95M      95 p9CKS
Beads        95M     95      p9CKS
46.9 –
32.7 –
30.2 –
kDa
97.4 –
66.2 –
45.0 –
31.0 –
1(S6K)
2 (CaMKII)
Cyclin B
CDK1
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that p35, the CDK5 activator, and p25, its proteolytic
cleavage product, are present (but barely detectable by
silver staining) on 95 matrix loaded with brain extracts.
There is apparently much more CDK5 than p35/p25, in
other words, there is a dominant level of monomeric
CDK5 (data not shown). Erk1, Erk2 and CDK5 did not
bind to 95 when immobilised through the N9 position
(95N9; Figure 8b), consistent with an orientation of the
inhibitor similar to that observed in the CDK2–purvalanol
B crystal structure. All three proteins bound to 95 immo-
bilised through the aniline substituent, even when the
sidechain was shortened by five atoms (95s; Figures 1 and
8b). As an additional control experiment, we added
increasing amounts of ATP to the brain extracts before
incubation with 95 matrix. This led to a gradual decrease
of CDK5 and Erk1/2 binding to the matrix, confirming the
true competitive ATP-binding nature of the interaction
with the matrix (data not shown). Similarly addition of
increasing levels of free 95 lead to a decreasing binding of
the kinases to the 95 matrix (data not shown).
Human cell lines 
Extracts prepared from exponentially growing MCF-7 cells
were loaded on 95 and 95M matrices. One principal protein
was found to bind specifically to 95 matrix (Figure 9, left).
Microsequencing of an internal peptide revealed its iden-
tity to be Erk2 (Figure 2), which was further confirmed by
western blotting with anti-Erk2 antibodies (Figure 9, right).
This binding of Erk2 was confirmed in several other cell
lines (data not shown). 
Protozoan parasites
Preliminary experiments have shown that purvalanol-
derived compounds inhibit the proliferation of several
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Figure 5
CDK1/cyclin B and three other proteins from
lugworm oocytes and two proteins from sea
urchin eggs bind to 95 matrix. Extracts from
(a) lugworm metaphase oocytes or (b) sea
urchin eggs were loaded on 95M and 95
matrices. Bound proteins were resolved by
SDS–PAGE and revealed by silver staining.
Proteins 1, 2 and 3 (lugworm) were further
processed for microsequencing and identified
as S6 kinase 2 (protein 1) and Erk1 (protein
3) (Figure 2). The sea urchin eggs provided
two proteins, one of them co-migrating with
CDK1/2 as revealed by immuno-reactivity with
anti-PSTAIRE antibodies (right).
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2 (?)
3 (Erk1)
kDa
95M 95
Sea urchin eggs
kDa
 95M  95 95  95M
0 min 90 min
– CDK1
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21.5 –  
min 90 min95
(a) (b)
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Figure 4
Binding of proteins 1 and 2 is independent of CDK1/cyclin B.
Extracts from starfish oocytes were depleted on p9CKShs1-sepharose
(p9), on control ethanolamine-sepharose beads (eth) or on 95M matrix
before loading on 95 matrix. Bound proteins were resolved by
SDS–PAGE and visualised (a) by western blotting with anti-PSTAIRE
antibodies and (b) by silver staining. CDK1 is visualised by the anti-
PSTAIRE cross-reactivity. 
Starfish oocytes
Beads    
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2 (CaMKII)
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human protozoan parasites (data not shown). In an effort
to define the intraparasitic targets, the affinity chromato-
graphic methods described above were applied to the fol-
lowing parasites: Plasmodium falciparum, Leishmania
mexicana, Trypanosoma cruzi and Toxoplasma gondii.
Extracts of each parasite species were loaded on 95M and
95 matrices. The bound proteins were separated by
SDS–PAGE and visualized by silver staining (Figure 10).
A single 37 kDa protein in Plasmodium was found to bind
specifically to the 95 matrix (Figure 10a). We formally
identified it as P. falciparum casein kinase 1 (CK1) by
microsequencing [44]. CK1 was also identified as a major
95-binding protein in L. mexicana (Figure 10b) and in
T. cruzi (Figure 10c). Two other proteins from T. cruzi had
no known homologs (Figure 2). Finally, T. gondii provided
a single principal 95-binding protein (Figure 10d). It was
also identified as CK1 by microsequencing (Figure 2).
This protein was absent from 95 matrix loaded with an
extract of the host Vero cells. In contrast, these cells pro-
vided a protein migrating at the level of Erk2 (confirmed
by western blotting; data not shown).
Kinase selectivity of 95 and 97
The use of agarose-immobilised 95 as an affinity chro-
matography resin has allowed the identification of seven
kinases that interact specifically with 95, but not with 95M
(Figure 2). Although purvalanols were identified and opti-
mised as selective CDK inhibitors, we re-examined the
effect of 95 and its closely related, more cell-permeable
analog, 97 (Figure 1), on the kinases identified as potential
targets (Table 1). Roscovitine data are shown for compari-
son. Clearly, both 95 and 97 are very potent CDK
inhibitors, with IC50 values of less than 10 and 40 nM,
respectively. In contrast, they inhibit CK1, Erk1, Erk2, S6
kinase II and calmodulin-dependent kinase II only at
much higher doses (IC50 between 3 and 15 µM). Other
kinases are essentially insensitive including a variety of
protein kinase C isoforms, cAMP and cGMP-dependent
protein kinase, Raf kinase, c-jun amino-terminal kinase,
insulin-receptor tyrosine kinase and v-abl [10,38]. Mam-
malian CK1 is only moderately inhibited by 95 and 97.
CK1 from the protozoan parasites may show a different
sensitivity to these purines. Preliminary experiments with
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Figure 6
CDK1/cyclin B, Erk2 and six other proteins from Xenopus oocytes bind
to 95 matrix. Extracts from Xenopus prophase (P) and maturing (GVBD,
germinal vesicle breakdown) oocytes were loaded on 95M and 95
matrices. Bound proteins were resolved by SDS–PAGE and revealed
by (a) silver staining and (b) western blotting with anti-PSTAIRE and
anti-erk2 antibodies. (c) The 95-matrix-bound proteins were run on a
modified electrophoresis system to allow visualisation of the mobility
shift associated with Erk2 activation during maturation. Proteins 4 and
5 were further processed for microsequencing and identified as
calmodulin-dependent kinase 2 and Erk 2, respectively (Figure 2). 
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Figure 7
Proteins interacting with 95 matrix from various rat tissues. Extracts
from liver, brain, kidney, lung, muscle, spleen, heart and testes were
loaded on 95 matrix; a liver extract was also loaded on 95M matrix.
The bound proteins were resolved by SDS–PAGE, followed by silver
staining. Protein 1 (liver extract on 95M matrix) and protein 2 (liver
extract on 95 matrix) were microsequenced and identified as alcohol
dehydrogenase (AD) and biliverdin reductase (Bil. Red.),
respectively (Figure 2).
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P. falciparum CK1 show a higher sensitivity to 95
(IC50 ~0.3 µM; data not shown).
Discussion
The use of immobilised 95 and 95M has allowed the iden-
tification of three types of purine-binding proteins: pro-
teins binding specifically to 95, proteins binding
selectively to 95M and proteins binding to both resins. 
The first category of proteins discovered by this study
binds selectively to 95, but not to 95M. Besides biliverdin
reductase (rat liver, but possibly also kidney and heart; see
Figure 7), and some unidentified proteins, all 95-selective
proteins are kinases (seven were identified). According to a
phylogenetic clustering of all kinases of known sequence
[45], some of the kinases isolated specifically on the 95
matrix fall within a small subcluster of the so-called
‘CMGC’ group (CDK1, Erk 1 and Erk2), whereas others
fall in the OPK group XII (CK1), CaM kinase group
(CaMKII) and AGC subgroup VI (RS6K). The 95 matrix
thus recognizes kinases of diverse structures. The ability to
bind 95 matrix cannot be predicted by primary amino-acid
sequence; however, the binding of both Erks and CDKs is
in agreement with the crystal structure of CDK2 in
complex with purines [46,47,15], and in particular with 95
[10] and with the crystal structure of olomoucine in
complex with Erk2 [48] (the inhibitor shows an orientation
which is almost the same as olomoucine and purvalanol in
CDK2). In all crystal structures, the N6-benzylamino or
N6-anilino substituents are situated towards the outside of
the ATP-binding pocket, and are thus accessible to solvent
(for review see [10]). Therefore, the orientation of 95
immobilised on the beads as shown in Figure 1 is still com-
patible with an interaction with kinases. A different orien-
tation (95 N9-linked matrix; Figure 1) would be
incompatible with 95 binding to CDKs. As illustrated with
porcine brain extracts (Figure 8), but also seen with starfish
oocytes (data not shown), this orientation of 95, with
respect to agarose, totally abolishes the binding of proteins
to 95 matrix. The crystal structures also tell us that the
purine N6 acts as a hydrogen donor for the backbone car-
bonyl of Leu83. Methylation of N6 abolishes the possibil-
ity of such a hydrogen bond and introduces an
unfavourable steric interaction that results in inactivation of
the purine as a CDK inhibitor (see examples in [17,38]).
The N6 methylation would therefore be expected to
disrupt activity against any kinase that binds the inhibitor
in an orientation similar to that observed in the CDK2–pur-
valanol B co-crystal structure. In fact, immobilised 95M
does not bind any of the 95-binding kinases detected in
this study showing that this methylation generically
destroys kinase inhibitory activity as discussed above. 
Alcohol dehydrogenase from rat liver is the only protein
that we found to bind selectively to the 95M matrix
418 Chemistry & Biology 2000, Vol 7 No 6
Figure 9
MCF-7 cells contain a principal 95-binding protein. An MCF-7 cell line
extract was loaded on 95M and 95 matrices. The bound proteins were
resolved by SDS–PAGE, followed by silver staining (left) or Western
blotting with anti-Erk2 antibodies (right). Protein 1 was
microsequenced and identified as Erk2 (Figure 2).
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Figure 8
Three proteins from porcine brain interact with 95. (a) Extracts from
porcine brain were loaded on 95M and 95 matrix. The bound proteins
were resolved by SDS–PAGE, followed by silver staining. Proteins 1, 2
and 3 were microsequenced and identified as Erk1, Erk2 and CDK5,
respectively (Figure 2). (b) Extracts from porcine brain were loaded on
95M, 95N9, 95s and 95 matrix. The bound proteins were resolved by
SDS–PAGE, followed by Coomassie blue staining.
Porcine brain(a) (b)
 
kDa kDa
 
 
 
95M 95N9 95s 9595M 95
97.4 –
45.0 –
66.2 –
21.5 –
31.0 –
14.4 –
97.4 –
66.2 –
45.0 –
31.0 –
1
2
3
1 (Erk1)
2 (Erk2)
3 (CDK5)
Chemistry & Biology
cm7602.qxd  06/07/2000  03:49  Page 418
(Figure 7). A trace of a protein with similar electrophoretic
mobility was observed on 95 matrix loaded with rat liver
extract. All other tissues and cells that we tested did not
contain any 95M-specific binding proteins. The presence of
alcohol dehydrogenase in liver, and its binding to an alcohol
containing molecule such as purvalanol, is not a surprise. 
We encountered very few proteins interacting with both
resins. In the starfish oocyte example, a major 32 kDa
protein binds to 95 and 95M matrices, but also to p9CKShs1
beads (Figure 3). Its intensity is reduced after a passage on
any type of beads, including control ethanolamine-
sepharose, prior to loading on 95 matrix (Figure 4). This
ligand-independent binding suggests direct interactions
with agarose. 
The presence of very few proteins on immobilised 95, as
shown in the variety of models presented here, is consis-
tent with the strong selectivity exhibited by purvalanols,
in particular, and by 2,6,9-trisubstituted purines, in
general. The molecular basis for this exquisite selectivity
still remains to be understood. One important determinant
is the ability of the subset of kinases that can bind to pur-
valanol to accommodate a bulky N6 group. Although this
can be validated only for the kinases whose crystal struc-
tures have been solved (CDK2, Erk2 and CK1) it is also
likely to be true for CaMKII and the RS6K. The identifi-
cation on 95 matrix of kinases other than CDKs raises
several questions. Why do these kinases, which are less
sensitive to purines (Table 1), bind to the 95 matrix? Is
their lower affinity compensated by their cellular abun-
dance? Why, then, are there not more proteins binding to
the affinity matrix? Are some of these cellular kinases
modified post-translationally in such a way that their affin-
ity is enhanced compared with the in vitro expressed
kinases? The IC50 values have been determined on
recombinant enzymes that may be partially inactive owing
to improper folding or lack of adequate post-translational
modifications. A substantial proportion of the kinase may
still have the ability to trap the inhibitor while lacking
kinase activity. This would result in an apparent increase
of the IC50 value. Would specific inhibition of these appar-
ently low-affinity kinases enhance the in vivo efficiency of
purvalanols on CDKs? Erk1/2, RS6K and CaMKII are
likely to be expressed in most if not all the tissues that we
examined in this study. Why are they not recovered on 95
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Table 1
Selectivity of 95, 97 and roscovitine.
Enzyme 95 97 Roscovitine
CDK1/cyclin B 0.006 0.033 0.450
CDK2/cyclin A 0.006 0.028 0.700
CDK5/p25 0.006 0.020 0.160
CK1 (mammalian) >3.333 3.000 n.d.
Erk1 3.333 12.000 34.000
Erk2 1.000 2.400 14.000
S6 kinase (p70rsk) 15.000 8.300 130.000
CaM kinase II 13.000 5.500 32.000
The purified enzymes were assayed in the presence of an increasing
concentration of the inhibitors. The IC50 values was evaluated
graphically and are presented in µM; n.d., not determined.
CDK1/cyclin B is a native kinase from starfish oocytes, all other
kinases are recombinant mammalian enzymes.
Figure 10
Human protozoan parasites. Extracts from (a) P. falciparum,
(b) L. mexicana, (c) T. cruzi and (d) T. gondii were loaded on 95M and
95 matrices. The bound proteins were resolved by SDS–PAGE,
followed by silver staining. Proteins 1 from P. falciparum, L. mexicana,
T. cruzi and T. gondii were identified as CK1 (Figure 2). For
Toxoplasma, extracts of uninfected Vero cells were also loaded on the
affinity matrices (right).
T. cruzi
kDa
95M  95
Toxoplasma
kDa
95M 95 95
T. gondii Vero
kDa
Plasmodium
kDa
95 95M
1 (CK1)
Leishmania
 95M 95
– 97.4
– 66.2
– 45.0
– 31.0
– 14.4
– 21.5
97.4 –
66.2 –
45.0 –
31.0 –
14.4 –
21.5 –
(?) 2
(CK1) 1
(a)
(b)
97.4 –
66.2 –
45.0 –
31.0 –
97.4 –
66.2 –
45.0 –
31.0 –
21.5 –
14.4 –
1 (CK1)
2 (?)
3 (?)
1(CK1)
– Erk2
Chemistry & Biology
cm7602.qxd  06/07/2000  03:49  Page 419
matrix from all samples? There could be several reasons
for this, for example slight sequence differences that could
modify the affinity, different post-translational modifica-
tions or binding of various regulating proteins, which
could affect the interaction with the inhibitor, significant
variations in their abundance; or a combination of these
factors. In any case, interpretation of any cellular effects of
purvalanols clearly has to take into account the pattern of
95 binding proteins, as detected by our method. We feel
that this method validates the intracellular targets of 95
and provides a general approach to identify intracellular
targets of a defined compound. As an example, we have
shown that, despite their structural similarity, a few
purines (52, 97, 212) have different cellular effects (arrest
in M, in G2 and induction of apoptosis, respectively) [38].
Immobilisation of these compounds and affinity-chro-
matography purification of interacting proteins from a cel-
lular extract should provide a pattern of proteins specific
to each compound. These patterns of bound proteins
might allow the identification of the specific target(s)
responsible for each specific cellular effect.
The results obtained with protozoan parasites have to be
discussed separately. Indeed, we anticipated that their
CDKs would be divergent enough from mammalian
CDKs to present significant differences in sensitivity to
purvalanols. So far we have not identified any CDK-
related kinases on the 95 matrix, despite their definitive
presence in protozoan parasites [49]. Surprisingly, CK1
was detected on 95 matrix loaded with extracts of four dif-
ferent species of parasites. This raises several questions.
Why did we never detect any 95-binding CK1 with mam-
malian tissues? What is the molecular basis for this differ-
ence, despite the extreme conservation of CK1 structure?
Are the affinities of protozoan CK1 for purvalanols, and
thereby their sensitivity to these compounds, much
higher? If this were the case, CK1s from protozoan para-
sites would be promising screening targets for the identifi-
cation of new molecules effective against protozoan
parasites. The cloning, expression and testing of these
CK1s, and their comparison with their mammalian
homologs, is an obvious priority for us. The P. falciparum
CK1 gene has already been characterised [44]; we are cur-
rently performing experiments to determine its in vitro
susceptibility to 95 and related purines.
The presence of a very limited set of 95-binding proteins
in brain is encouraging. Interested by the design of com-
pounds active against neurodegenerative disorders, we are
mostly looking for inhibitors of CDK5 and GSK-3. Given
the interaction of Erk1/Erk2 with purvalanols shown here,
the screening for CDK5 inhibitors should incorporate a
parallel screen with Erk1/Erk2. Whole brain extracts were
used in this study. We clearly need to study the pattern of
95-binding proteins in various regions of the brain, after
precise anatomical dissections. Also, the comparison of
95-binding proteins obtained from nervous tissues repre-
sentative of various pathological situations may reveal new
targets to go after. 
The oocytes and eggs presented in this study constitute
powerful models for the study of cell-cycle regulation.
Identification of their purvalanol targets will allow a better
comprehension of some cellular processes involved in
control of cell division. It will also facilitate the optimisa-
tion of new anti-mitotic compounds of therapeutic poten-
tial in cancer. 
Finally, identification of 95-binding proteins in liver pro-
vides some clues on the metabolism of purvalanols by a
whole organism. This may help in the design of more
metabolism-resistant compounds, and in the understand-
ing and possibly avoidance of undesired side effects
of purvalanols. 
In summary, we have designed a simple batch affinity
chromatography method that allows the rapid purification,
detection and identification of intracellular targets of CDK
inhibitors. This method has been successfully applied to
purvalanols, but could be extended to all other known
CDK inhibitors, in particular those that have been co-crys-
tallised with CDK2. This purification method could
readily be adapted to a 96-well format whereby a library of
immobilized purine compounds could be screened to
identify multiple targets in parallel. This approach would
allow the unbiased identification of potential targets for
the library as a whole, as well as specific library members.
Indeed this approach might be applied to combinatorial
libraries of other directed scaffolds (e.g. statine deriva-
tives, hydroxamates) to rapidly identify inhibitor–receptor
pairs on a genome-wide level. Furthermore, knowledge of
the pattern of target proteins allows a better interpretation
of the cellular effects of the inhibitors and will also help in
orientating the optimisation of compounds for therapeutic
applications against cancer, neurodegenerative disorders
and protozoan parasites. 
Significance
Chemical inhibitors of cyclin-dependent kinases (CDKs)
have great therapeutic potential against various prolifer-
ative and neurodegenerative disorders. The founding
member of the family of 2,6,9-trisubstituted purines, olo-
moucine, has been optimized for activity against
CDK1/cyclin B by combinatorial and medicinal chem-
istry efforts to yield the purvalanol inhibitors
(IC50 = 6 nM). Despite their excellent in vitro selectivity
against a collection of 25 purified kinases and numerous
cell-based studies that support their action against
CDKs, their actual intracellular targets remain unveri-
fied. To address this question, purvalanol B (95) and a
N6-methylated, CDK-inactive derivative (95M) were
immobilized to an agarose matrix. Extracts from a
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diverse collection of cell types and organisms were
screened for purvalanol-B-binding proteins. In addition
to validating CDKs as intracellular targets, a variety of
protein kinases (Erk1, Erk2, RS6K, CaMKII and CK1)
were specifically recovered from the 95 matrix. Several
of the recovered kinases, including CaMKII, Erk1 and
Erk2, were inhibited by the purvalanols with IC50
values 1000-fold higher than those measured for CDK1,
2 and 5, suggesting that their isolation may result from
higher cellular abundance. CK1 was identified as one of
the principal 95-matrix binding proteins in Plasmodium
falciparum, Trypanosoma cruzi, Leishmania mexicana and
Toxoplasma gondii. Purvalanol compounds were also
shown to inhibit the proliferation of these parasites, sug-
gesting that CK1 may serve as a valuable target for
further screening with libraries of 2,6,9-trisubstituted
purines. The ease with which a simple batchwise affinity
chromatography approach using two purine derivatives
resulted in the isolation of a small set of highly purified
and related kinases suggests that this approach may
serve as a general method for identifying the intracellu-
lar targets of a given ligand.
Materials and methods
Preparation of extracts
Various biological materials were used in this study (see Supplemen-
tary material): starfish and Arenicola oocytes, sea urchin eggs,
Xenopus oocytes and gonads, rat tissues, porcine brain, MCF-7 cells,
protozoan parasites (Plasmodium falciparum, Trypanosoma cruzi,
Leishmania mexicana, Toxoplasma gondii ). Tissues were weighed,
homogenised and sonicated in homogenisation buffer (2 ml per gram
of material). Homogenates were centrifuged for 10 min at 14,000g and
4°C. The supernatant was recovered and immediately loaded on the
affinity matrices. Cells were directly sonicated in homogenisation buffer
and processed the same way. 
Preparation and use of affinity reagents 
Purines (95, 95M) were coupled to Reactigel® agarose beads at a cal-
culated final concentration of 10–50 µmol/ml of resin. They were
stored at 4°C as a 33% (v/v) slurry in bead buffer. Just before use,
10 µl of packed beads were washed with 1 ml of bead buffer and
resuspended in 400 µl of this buffer. The cell/tissue supernatant
(400 µl) was then added; the tubes were rotated at 4°C for 30 min.
After a brief spin at 10,000g and removal of the supernatant, the beads
were washed four times with bead buffer before addition of 50 µl of
2× Laemmli sample buffer. When larger samples were prepared for
microsequencing, up to 25 ml of cell/tissue extracts were incubated
with 200–500 µl packed beads and 25 ml of bead buffer. The beads
were processed as described above and the bound proteins were
recovered with 300 µl of 2× Laemmli sample buffer. 
The CDK1/2-binding protein p9CKShs1 was purified from an overpro-
ducing strain of Escherichia coli and conjugated to CNBr-activated
sepharose 4B as described [40] at a concentration 3.9 mg p9CKShs1
per microlitre of gel (i.e. 0.5 µmol/ml of gel). P9CKShs1-sepharose beads
were kept at 4°C as a 20% (v/v) suspension in bead buffer. Cell
extracts (400 µl) were incubated with 10 µl packed beads + 400 µl
bead buffer for 30 min. The beads were processed as described for
the purine beads. 
Supplementary material
Supplementary material including details on chemicals and antibod-
ies, buffers, biological material, electrophoresis and western blotting,
identification of purified proteins and kinase assays is available at
http://current-biology.com/supmat/supmatin.htm.
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